Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders

开发 ITI-333，一种 μ-阿片受体部分激动剂和 5HT2A 和 D1 受体拮抗剂，用于治疗阿片类药物使用障碍

• 批准号: 9841388
• 负责人: SANDRA D COMER
• 金额: $ 291.71万
• 依托单位: INTRA-CELLULAR THERAPIES, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-01-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9841388
• 关键词: Acute; Adverse event; Affinity; Agonist; Animals; Anxiety; Binding; Biological Products; Biotechnology; Brain; Central Nervous System Diseases; Clinical; Clinical Paths; Clinical Research; Clinical Trials; Collaborations; Conduct Clinical Trials; Data; Development; Development Plans; Dopamine; Dopamine D1 Receptor; Dose; Dose-Limiting; Double-Blind Method; Drug Kinetics; Exhibits; Fentanyl; Formulation; Funding; Future; Goals; Grant; HTR2A gene; Heroin; Heroin Users; Human; Image; Individual; Inpatients; Maintenance; Maximum Tolerated Dose; Modeling; Morphine; National Institute of Drug Abuse; Opiate Addiction; Opioid; Opioid Antagonist; Opioid Receptor; Opioid agonist; Outcome; Overdose; Parents; Pathway interactions; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Phase; Placebos; Plasma; Positron; Precipitation; Principal Investigator; Regimen; Relapse; Research Personnel; Route; Safety; Serotonin; Serotonin Receptor 5-HT2A; Signal Transduction; Therapeutic; Therapeutic Index; Therapeutic Uses; Toxicology; Withdrawal; associated symptom; base; carfentanil; clinical development; depressive symptoms; design; effective therapy; first-in-human; healthy volunteer; illicit opioid; in vivo; innovation; molecular drug target; mu opioid receptors; novel; opioid abuse; opioid use; opioid use disorder; opioid user; opioid withdrawal; phase 2 study; prescription opioid; prevent; programs; radioligand; receptor; research clinical testing; small molecule; symptom treatment; volunteer

RFA-DA-19-002 Principal Investigator/PD: Vanover, Kimberly E. Project Summary/Abstract Intra-Cellular Therapies Inc (ITI), a clinical-stage biopharmaceutical company, is developing ITI-333, a novel compound with high affinity activity at mu opiate (MOP), 5-HT2A, and D1 receptors. The nonclinical profile of ITI-333 suggests a promising medication, lacking abuse liability, with partial agonist activity at MOP receptors useful for treatment of opiate withdrawal in individuals with Opioid Use Disorders (OUD). ITI is currently completing IND-enabling nonclinical safety, toxicology, pharmacokinetic and manufacturing activities, with the goal of launching Phase 1 human clinical evaluation of ITI-333 in healthy volunteers in Q1 2019. ITI seeks to partner with NIDA in the development of this compound for a novel and safe therapeutic for use in treating OUD, requesting support of clinical development of ITI-333, while committing significant internal funds to a parallel program of non-clinical development and CMC activities in support of the clinical plan. To this end, we submit this application, “Development of ITI-333, a µ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders” to NIDA RFA-DA-19-002, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3). Here, we propose a 2-year UG3 program, including a First-in-Man, single ascending dose (SAD) study (ITI-333-001) to assess the safety, tolerability and pharmacokinetics of ITI-333 in healthy volunteers. The safety, tolerability, and pharmacokinetics of multiple, ascending doses (MAD) of ITI-333 will then be evaluated in a single-center in-patient study (ITI-333-002) with the goal of determining a maximally- tolerated dose (MTD). Both studies will be conducted in collaboration with Clinilabs, a NYC-based CRO. In parallel with the MAD study, we will characterize the in vivo receptor pharmacology of ITI-333 at MOP, 5- HT2A, and D1 receptors in human brain using PET imaging (with Dr. Dean Wong, JHU, ITI-333-003), thereby leveraging our SAD data to clinically validate the mechanism of action of ITI-333 and to inform Phase 2 dose selection. These data will enable us to launch a 3-year UH3 program exploring the human abuse liability (HAL) and functional pharmacology of ITI-333 in collaboration with Dr. Sandra Comer (CUMC), a clinical expert in opioid use and abuse. The HAL study (Phase 2a, ITI-333-004) will characterize the opioid receptor antagonist/partial agonist profile of ITI-333 in humans to explore potential abuse liability in humans. Additional Phase 2 studies will evaluate the in vivo functional pharmacology of ITI-333 in a model of withdrawal precipitation in non-treatment seeking heroin users (ITI-333-005) and in a model of mu-opioid receptor blockade in treatment-seeking heroin users (ITI-333-006). Together, we believe this clinical development plan with inform further development of ITI-333 and the selection of a cogent Phase 3 clinical path toward FDA approval as a medication for the treatment of OUD.

RFA-DA-19-002首席研究员/PD：Kimberly E. Vanover。 项目摘要/摘要 临床阶段生物制药公司的细胞内治疗公司（ITI）正在开发ITI-333，这是一种小说 MU优化时具有高亲和力活性的化合物（MOP），5-HT2A和D1受体。非临床轮廓 ITI-333提出了一种有希望的药物，缺乏虐待责任，并在拖把上进行部分激动剂活动 可用于治疗阿片类药物使用障碍患者（OUD）的优化戒断的受体。 Iti是 目前正在完成非临床安全，毒理学，药代动力学和制造业 活动，目的是在第1季度的健康志愿者中启动ITI-333的人类ITI-333的临床评估 2019年。ITI试图与NIDA合作，开发这种化合物，以进行新颖且安全的治疗 用于治疗OUD，请求支持ITI-333的临床开发，同时进行大量 内部资金用于非临床开发和CMC活动的并行计划，以支持临床 计划。为此，我们提交了此申请：“ ITI-333的开发，µ-阿片受体部分 激动剂和5HT2A和D1受体拮抗剂，用于治疗阿片类药物使用障碍” RFA-DA-19-002，开发用于预防和治疗阿片类药物使用障碍和过量药物的药物 （UG3/UH3）。在这里，我们提出了一项为期两年的UG3计划 （SAD）研究（ITI-333-001）评估ITI-333的安全性，耐受性和药代动力学 志愿者。 ITI-333的多种，上升剂量（MAD）的安全性，耐受性和药代动力学将会 然后在单中心的住院研究（ITI-333-002）中评估，目的是确定最大 耐受剂量（MTD）。这两项研究将与基于纽约市的CRO临床单位合作进行。在 与MAD研究并行，我们将表征MOP上ITI-333的体内受体药理学，5-- 使用PET成像（与Dean Wong博士，Jhu，ITI-333-003）中的HT2A和D1受体，从而 利用我们的悲伤数据来临床验证ITI-333的作用机理，并告知第2阶段 剂量选择。这些数据将使我们能够启动一个为期3年的UH3计划，以探索人类虐待 ITI-333的责任（HAL）和功能性药理学与Sandra Comer博士（CUMC）合作 卵巢药物使用和滥用方面的临床专家。 HAL研究（第2A阶段，ITI-333-004）将表征Opioid 人类ITI-333的受体拮抗剂/部分激动剂概况，以探索人类潜在的虐待责任。 其他阶段2研究将评估ITI-333的体内功能药理学 寻求海洛因使用者（ITI-333-005）的非治疗降水和MU-Apioid模型 寻求治疗的海洛因使用者（ITI-333-006）中的受体封锁。在一起，我们相信这个临床 开发计划，并进一步开发ITI-333和企业3阶段临床的选择 通往FDA批准的路径是治疗OUD的药物。